CEPH buys full rights to Abbott's Gabitril

Cephalon (CEPH) will pay ABT $100 million over four years for exclusive U.S. rights to market Gabitril tiagabine. The companies have been co-promoting the ABT anti-epileptic since June 1999. CEPH will...